Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCZ | Q05513 | 10/20 | 1.00 |
| ▸ | PRKCI | P41743 | 2/20 | 0.72 |
| ▸ | MAPT | P10636 | 7/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 3/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | PLK4 | O00444 | 1/20 | 0.44 |
| ▸ | JAK2 | O60674 | 1/20 | 0.44 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.44 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.44 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.44 |
| ▸ | PRKCG | P05129 | 1/20 | 0.44 |
| ▸ | LCK | P06239 | 1/20 | 0.44 |
| ▸ | FYN | P06241 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3386676 | 0.84 | PRKCZ (1.00) | PRKCZPRKCIMAPTALDH1A1POLB | |
| SCHEMBL2369127 | 0.82 | PRKCZ (0.69) | PRKCZPRKCIMAPTALDH1A1HSD17B10 | |
| SCHEMBL17356378 | 0.80 | MAPT (0.72) | PRKCZPRKCIMAPTALDH1A1POLB | |
| SCHEMBL14123479 | 0.79 | PRKCZ (0.66) | PRKCZPRKCIMAPTALDH1A1POLB | |
| SCHEMBL10297769 | 0.79 | PRKCZ (0.70) | PRKCZPRKCIMAPTALDH1A1POLB | |
| SCHEMBL13837635 | 0.78 | PRKCZ (1.00) | PRKCZPRKCIMAPTALDH1A1HSD17B10 | |
| SCHEMBL17356385 | 0.78 | MAPT (0.73) | PRKCZPRKCIMAPTALDH1A1POLB | |
| SCHEMBL12632700 | 0.78 | PRKCZ (1.00) | PRKCZPRKCIMAPTALDH1A1POLB | |
| SCHEMBL31060884 | 0.78 | PRKCZ (1.00) | PRKCZPRKCIMAPTALDH1A1POLB | |
| SCHEMBL20635749 | 0.77 | PRKCZ (0.87) | PRKCZPRKCIMAPTALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9301965-B2 | Method of treating ovarian cancer using a PKC inhibitor | UNIVERSITY OF SOUTH FLORIDA (US) | 2016-04-05 | — | — | US | disclosed |
| US-9301965-B2 | Method of treating ovarian cancer using a PKC inhibitor | UNIVERSITY OF SOUTH FLORIDA (US) | 2016-04-05 | — | — | US | disclosed |
| US-20150366883-A1 | METHOD OF TREATING OVARIAN CANCER USING A PKC INHIBITOR | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-12-24 | — | — | US | disclosed |
| US-20150366883-A1 | METHOD OF TREATING OVARIAN CANCER USING A PKC INHIBITOR | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-12-24 | — | — | US | disclosed |
| US-8889672-B2 | Compounds, formulations, and methods of protein kinase C inhibition | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2014-11-18 | — | — | US | disclosed |
| US-8889672-B2 | Compounds, formulations, and methods of protein kinase C inhibition | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2014-11-18 | — | — | US | disclosed |
| US-20120302561-A1 | Compounds, Formulations, and Methods of Protein Kinase C Inhibition | THE PENN STATE RESEARCH FOUNDATION (US) | 2012-11-29 | — | — | US | disclosed |
| US-20120302561-A1 | Compounds, Formulations, and Methods of Protein Kinase C Inhibition | THE PENN STATE RESEARCH FOUNDATION (US) | 2012-11-29 | — | — | US | disclosed |
| WO-2012149452-A1 | COMPOUNDS, FORMULATIONS, AND METHODS OF PROTEIN KINASE C INHIBITION | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2012-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150366883-A1 | METHOD OF TREATING OVARIAN CANCER USING A PKC INHIBITOR | PRKD1, PRKCI, ACP3 | PRKCZ 16/4885PRKCI 2/4885MAPT 4352/4885 |
| US-20120302561-A1 | Compounds, Formulations, and Methods of Protein Kinase C Inhibition | PRKCA, PRKCH, PRKCI | PRKCZ 5/4885PRKCI 3/4885MAPT 3173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.